Nutriband CEO Discusses AVERSA Technology's Role in Addressing Opioid Crisis on Podcast
Nutriband Inc. CEO Gareth Sheridan highlighted the company's AVERSA abuse-deterrent transdermal technology on a podcast, emphasizing its potential to reduce misuse of high-risk drugs like fentanyl while maintaining patient access.
Nutriband Inc. (NASDAQ: NTRB) announced that CEO and Co-Founder Gareth Sheridan appeared on the Jack Neel Podcast to discuss the opioid crisis and the company's AVERSA abuse-deterrent transdermal technology. The episode detailed how AVERSA is designed to reduce misuse, diversion, and accidental exposure of high-risk drugs such as fentanyl while maintaining patient access, supported by a broad global patent portfolio.
The company's lead product under development is an abuse-deterrent fentanyl patch incorporating AVERSA technology, which can be integrated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. This development comes amid growing concerns about opioid-related deaths and the need for safer pharmaceutical delivery systems that balance pain management with abuse prevention.
Nutriband's approach represents a significant advancement in transdermal pharmaceutical products, addressing a critical public health challenge through technological innovation. The company's website at https://www.nutriband.com provides additional information about their development portfolio, though material from the website is not part of the official announcement.
The broader implications of this technology extend beyond individual patient safety to potential systemic impacts on healthcare costs, regulatory approaches to controlled substances, and the pharmaceutical industry's role in addressing substance abuse epidemics. As noted in the company's newsroom at https://ibn.fm/NTRB, ongoing developments in this space continue to attract attention from investors and healthcare professionals alike.
BioMedWire, the specialized communications platform that distributed this announcement, focuses on biotechnology, biomedical sciences, and life sciences sectors as part of the Dynamic Brand Portfolio at IBN. The platform provides various distribution services including wire solutions, editorial syndication, press release enhancement, and social media distribution through their network. More information about their services is available at https://www.BioMedWire.com, with full terms of use and disclaimers accessible at https://www.BioMedWire.com/Disclaimer.
The discussion of AVERSA technology on the podcast highlights how pharmaceutical innovation intersects with public health policy, particularly regarding controlled substances with high abuse potential. As regulatory bodies continue to seek solutions to the opioid crisis, technologies like AVERSA that maintain therapeutic access while reducing abuse risks represent an important direction for pharmaceutical development and pain management strategies.